It has been reported that some liver tumors, including HCC, cholangiocarcinoma, and hepatocholangiocarcinoma
, may undergo sarcomatous change , a phenomenon closely associated with epithelial-mesenchymal transition (EMT) and neoplastic progression [4, 5].
ICD-Oncology code C22.0 was used to identify patients with PHN that included the following diagnostic groups: hepatocellular cancer, hepatic cell carcinoma, mixed hepatocellular carcinoma, fibrolamellar carcinoma, hepatocholangiolitic carcinoma, mixed bile duct with hepatocellular carcinoma, cholangiocarcinoma with hepatocellular carcinoma, cholangiohepatoma, hepatocarcinoma, hepatocholangiocarcinoma
, and malignant embryonal hepatoma.
In one poorly differentiated case, reported as possible hepatocholangiocarcinoma
, Hep Par-1 and CK7 was positive in the tumor cells, and polyclonal carcinoembryonic antigen (pCEA) and CK20 were negative.
Although these represent very few cases, this suggests either a resistance to ablation or a tendency for rapid regrowth following ablation for combined hepatocholangiocarcinomas
. One published case report describes rapid progression of a confirmed hepatocholangiocarcinoma
When Yiamouyiannis analyzed the same data, he found mice with a particularly rare form of liver cancer, known as hepatocholangiocarcinoma
. This cancer is so rare, according to Yiamouyiannis, that the odds of its appearance in this study by chance are 1 in 2 million in male mice and 1 in 100,000 in female mice.
This conclusion was based on increases in male and female rats of hepatocellular carcinoma and hepatocholangiocarcinoma
, neuroendocrine tumors of the glandular stomach, and the observation of other tumor types in several other tissues, and the primary tumors observed in B6C3[F.sub.1] mice were hepatocellular carcinoma in male and female mice and increased neuroendocrine tumors of the glandular stomach in male mice.